Could Ajovy worsen seizure control or affect epilepsy medications?

The short version: the retrieved evidence does not test whether Ajovy worsens seizures or interacts with epilepsy drugs, so no grounded answer exists for that specific question.

The studies here all cover fremanezumab for migraine, not epilepsy. None of them measure seizure frequency, seizure threshold, or blood levels of antiseizure medications [1][2][3]. The closest material is a 2012 review of antiepileptic drugs used for migraine prevention, which covers valproate, topiramate, zonisamide, and gabapentin, but says nothing about CGRP antibodies or drug interactions [5]. That is a gap in this search, not proof of safety.

What the evidence does show is that fremanezumab reduces migraine days in controlled trials, with 50% responder rates of roughly 40-60% in episodic and 30-60% in chronic migraine [4]. Adverse events are mainly injection-site reactions, with no cerebrovascular or cardiovascular effects reported in one review [2]. None of that addresses your epilepsy question.

The mechanism concern is real but untested here. CGRP is involved in vasodilation and neurogenic inflammation, so blocking it could theoretically alter blood-brain barrier permeability or neuronal excitability. But no study in this set examines that in people with seizures. No study here checks whether Ajovy changes how the liver or kidneys clear antiseizure drugs, which is where a real interaction would show up.

My call: the evidence does not answer whether Ajovy worsens seizure control or interacts with epilepsy medications. That question is unstudied in everything retrieved here. Confidence: not clear.